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Circulating Endothelial Cells as a Marker of Ongoing Vascular
Disease in Systemic Sclerosis
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and Agostino Cortelezzi4
Objective. Circulating endothelial cells (CECs)
have been described in different conditions involving
vascular injury. Vascular abnormalities play a key role
in the pathogenesis of systemic sclerosis (SSc). The aim
of this study was to search for the presence of CECs in
patients with SSc and to evaluate their clinical associ-
ations and possible pathogenic role.
Methods. The study cohort included 46 patients
with SSc and 40 healthy controls. Five-parameter,
3-color flow cytometry was performed with a FACScan.
CECs were defined as CD45 negative, CD34 positive,
and P1H12 positive, and activated CECs were defined as
CD45 negative and P1H12 positive, CD62 positive, or
CD106 positive. Progenitors were identified as CD34
positive and CD133 positive.
Results. Total and activated CEC counts were
significantly higher in SSc patients compared with
healthy controls and were positively correlated with the
disease activity score. With respect to visceral involve-
ment, significant correlation was observed between the
CEC number and the severity of pulmonary hyperten-
sion. High levels of endothelial progenitors were ob-
served in patients with SSc, and the counts were higher
in the early stages of disease.
Conclusion. The presence of CECs in patients
with SSc may represent direct evidence of endothelial
disease and may be a promising new clinical marker
for active SSc. Notably, the association between CECs
and pulmonary hypertension and impaired carbon mon-
oxide diffusing capacity was evident in patients with
limited cutaneous SSc only, suggesting an important
role for CECs in this disease subset with prominent
vascular changes. Detection of circulating endothelial
progenitors may represent a response to vascular isch-
emia in early SSc, as an attempt at revascularization.
Systemic sclerosis (SSc) is a connective tissue
disease of unknown etiology and pathogenesis that is
characterized by immunologic abnormalities, microangi-
opathy, and excessive deposition of collagen (1–3). Clin-
ical and pathologic findings of vascular damage and
endothelial cell activation strongly support the hypothe-
sis of a unique vascular disease as an important and
primary process in scleroderma (4,5). It is likely that
prolonged endothelial cell perturbation and activation
induced by ischemia and reperfusion lead to dysfunction
and irreversible loss of integrity, with cell detachment
and persistent tissue injury. Although an extensive body
of literature supports the pathogenic importance of SSc
vasculopathy (6), research in this field has been limited
by the relative inaccessibility of vascular endothelium.
In certain disease conditions, circulating endo-
thelial cells (CECs) detached from affected blood ves-
sels provide useful material for studying vascular injury.
In humans, CECs have been detected in diverse condi-
tions having in common endothelial damage, such as
coronary angioplasty, acute coronary syndrome, sickle
cell anemia, thrombotic thrombocytopenic purpura, in-
fection with Rickettsia conorii or cytomegalovirus, Beh-
c¸et’s disease, systemic lupus erythematosus (SLE), and
small-vessel vasculitis (7–15). Moreover, it has been
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suggested that in response to severe ischemia or cyto-
kine stimuli, circulating endothelial cell progenitors
(CEPs) increase and home into sites of angiogenesis and/or
vascular damage, and consequently contribute to neovas-
cularization and/or wound-healing processes (16–18).
The presence of CECs in these vascular disorders
likely provides direct evidence of endothelial injury,
even though it is unknown whether CECs correlate with
the extent of endothelial lesions. Nevertheless, detection
and analysis of CEC phenotype and/or CEPs may be an
informative tool to study vascular dysfunction. Based on
the hypothesis that severe vascular damage associated
with SSc would result in endothelial shedding, we per-
formed a cytometric evaluation of the number and
surface phenotype of CECs in patients with SSc. We also
determined whether the presence of CECs is associated
with disease activity, clinical features, and/or plasma
markers of endothelial activation.
A further goal of this study was to gain additional
insight into the problem of vasculogenesis in SSc. Based
on the hypothesis that the ischemic damage in SSc
tissues might be associated with an attempt to recruit
endothelial progenitors to sites of vascular damage, we
assessed the presence of CEPs in peripheral blood
obtained from patients with SSc and studied the corre-
lation between CECs and CEPs and known angiogenic
factors.
PATIENTS AND METHODS
Patients. Forty-six consecutive patients referred to our
institution were included in the study. Informed consent was
given by all patients. All patients studied fulfilled the American
College of Rheumatology (formerly, the American Rheuma-
tism Association) criteria for the classification of SSc (19).
Patients were grouped according to the 2-cutaneous subset
classification (1,20); namely, patients were classified as having
limited cutaneous SSc (lcSSc; sclerosis of both distal extremi-
ties, not the elbow and knees, with or without sclerosis of the
neck and face) or diffuse cutaneous SSc (dcSSc; sclerosis of
both distal and proximal extremities, with or without truncal
involvement). Patients with overlap symptoms to other con-
nective diseases were excluded from the study.
The median disease duration was measured from the
onset of the first signs and symptoms compatible with this
disease (Raynaud’s phenomenon, puffy hands, sclerodactyly
with or without proximal scleroderma, dyspnea, and/or dyspha-
gia).
All patients were treated with calcium channel block-
ers and/or angiotensin-converting enzyme inhibitors. Twenty-
nine of 46 patients received therapy with intravenous prosta-
noid. The blood samples for CEC assay were always obtained
before an iloprost infusion, and at least 1 month after the
previous infusion. Because immunosuppressive drugs might
theoretically interfere with CEC and CEP levels, patients
receiving disease-modifying treatments (corticosteroids, cyclo-
phosphamide, or methotrexate) were not included in the study.
Forty healthy subjects, matched with SSc patients for
sex and age, were also included in this study as controls.
Clinical assessment. The clinical and laboratory data
reported in this study are those obtained when the blood
samples were collected. The patients included in the study had
been evaluated for organ involvement at least 1 month before
the blood sampling. Organ involvement was assessed according
to previously described criteria (20). In particular, skin involve-
ment was assessed by a modified Rodnan skin thickness score.
The occurrence of pulmonary involvement was defined by
pulmonary hypertension and/or bibasilar fibrosis on standard
chest radiographs and/or restrictive lung disease. Pulmonary
function was assessed by vital capacity, as measured by a dry
spirometer, and by carbon monoxide diffusing capacity
(DLCO), as measured by the single-breath method, both of
which are expressed as percentages. Pulmonary artery pressure
was detected by color Doppler echocardiography. Joint/tendon
involvement was defined by the detection of symmetric syno-
vitis, flexion contractures, and tendon friction rubs (21). Mus-
cle involvement was evaluated as isolated muscle weakness or
weakness associated with elevated levels of serum creatine
kinase with or without electromyographic or histologic changes
of inflammatory myopathy. The degree of inflammatory activ-
ity was determined by the erythrocyte sedimentation rate
(ESR) and the C-reactive protein (CRP) level.
For all patients with SSc, disease activity was assessed
using the activity indices described by the European Sclero-
derma Study Group (22,23). According to these criteria,
disease was considered active if the sum of the scores for
detected items was 3. Disease stages were defined as sug-
gested by Medsger and Steen (24): early lcSSc (disease dura-
tion 5 years), intermediate/late lcSSc (disease duration 5
years), early dcSSc (disease duration 3 years), and
intermediate/late dcSSc (disease duration 3 years).
Detection of CECs by flow cytometry analysis. Two
hundred microliters of peripheral blood in sodium heparin was
labeled with 10 l of a panel of fluorescein isothiocyanate
(FITC)–, R-phycoerythrin (R-PE)–, or peridin chlorophyll
protein–conjugated antibodies anti-CD45, anti-CD34, anti-
CD106, anti-CD133, anti-CD62, and anti-P1H12, for 20 min-
utes at room temperature. After conjugation, red blood cells
were lysed by incubating in FACS lysing solution (Becton
Dickinson, San Jose, CA) for 15 minutes at room temperature.
White blood cell pellets were then washed twice in FACSFlow
solution (Becton Dickinson).
Appropriate analysis gates were used to enumerate
total and activated CECs and CEPs. CECs were defined as
negative for CD45 and positive for CD34 and P1H12 (9,25).
Activated CECs were defined as negative for CD45, positive
for P1H12, and positive for CD62 or CD106 (9,25). CD133 and
CD34 surface expression characterized CEPs (17). Five-para-
meter, 3-color flow cytometry was performed with a FACScan
flow cytometer with a 15-mW argon laser (excitation at 488
mm) (Becton Dickinson). The sensitivity of fluorescence de-
tectors was set and monitored using CaliBRITE beads (Becton
Dickinson) according to the manufacturer’s recommendations.
Cells stained with isotypic controls for IgG1–FITC or R-PE
were used as negative controls (26). At least 100,000 (typically
300,000) cells per sample were acquired; analyses were consid-
ered informative when adequate numbers of events (100)
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were collected in the CEC enumeration gates (25). Data were
analyzed with CellQuest software (Becton Dickinson).
Detection of vascular endothelial growth factor
(VEGF) and soluble E-selectin. Plasma concentrations of
soluble E-selectin and VEGF were assessed by commercial
enzyme-linked immunosorbent assays (R&D Systems, Minne-
apolis, MN) and calculated using a standard curve generated
with specific standards, according to the manufacturer’s rec-
ommendations.
Statistical analysis. Comparisons of CEC levels be-
tween patients with SSc and healthy controls were performed
by the Mann-Whitney rank sum test. P values less than 0.05
were considered significant. In addition, correlations between
CEC number and different SSc disease parameters were
assessed by Spearman’s rank correlation test.
RESULTS
Demographic and clinical features of patients.
The present study included 45 women and 1 man, with a
median age of 56 years (range 24–72 years). Twenty-two
Table 1. Assessment of disease activity in patients with systemic sclerosis*
Patient
no.
Modified
Rodnan
score 14 Scleroderma

skin
Digital
necrosis

vascular Arthritis
DLCO
80%

Heart/
lung
ESR
30
mm/hour
Hypocomple-
mentemia
Total
maximum
DA score
1 1 1 2 0.5 0.5 0 0 0 0 0 5
2 0 0 0 0 0 0 0.5 2 0 0 2.5
3 0 0 0 0.5 0.5 0.5 0.5 0 0 1 3
4 0 0 0 0.5 0.5 0.5 0 0 0 0 1.5
5 0 0 0 0.5 0.5 0 0.5 0 0 0 1.5
6 0 0 0 0 0 0 0.5 2 0 0 2.5
7 1 0 0 0.5 0 0 0.5 0 0 0 2
8 1 1 2 0 0.5 0.5 0.5 2 1.5 1 10
9 1 0 0 0.5 0.5 0 0.5 0 0 0 2.5
10 0 0 2 0 0.5 0 0.5 2 1.5 0 6.5
11 0 0 0 0.5 0 0 0 2 0 0 2.5
12 0 0 0 0 0 0.5 0.5 0 1.5 1 3.5
13 0 0 0 0 0 0.5 0.5 0 0 0 1
14 0 0 0 0 0 0 0.5 2 0 0 2.5
15 0 1 2 0 0.5 0 0.5 2 0 0 6
16 1 0 0 0.5 0.5 0.5 0.5 2 1.5 1 7.5
17 0 0 0 0.5 0.5 0.5 0 0 0 0 1.5
18 0 0 0 0 0.5 0 0.5 0 0 0 1
19 0 1 0 0 0.5 0 0.5 0 0 0 2
20 1 0 0 0 0 0 0 0 0 0 1
21 1 1 2 0 0.5 0.5 0.5 2 1.5 0 9
22 1 1 2 0 0 0 0.5 2 1.5 0 8
23 1 1 2 0 0.5 0 0.5 0 0 0 5
24 1 1 2 0.5 0 0 0.5 2 1.5 0 8.5
25 1 1 2 0.5 0.5 0 0.5 0 1.5 0 7
26 1 0 0 0 0.5 0.5 0 0 0 0 2
27 0 0 0 0 0.5 0.5 0.5 2 1.5 1 6
28 0 1 2 0.5 0.5 0 0.5 0 0 0 4.5
29 0 1 0 0 0.5 0.5 0 0 0 0 2
30 1 0 2 0 0.5 0 0.5 0 0 0 4
31 1 1 2 0.5 0 0 0.5 0 0 0 5
32 1 1 2 0.5 0.5 0 0.5 2 1.5 0 9
33 0 0 0 0 0 0.5 0.5 0 0 0 1
34 1 0 0 0 0 0 0 0 0 0 1
35 0 1 0 0 0.5 0 0.5 2 1.5 0 5.5
36 1 1 0 0 0 0 0.5 0 1.5 0 4
37 0 1 2 0 0 0 0.5 0 1.5 0 5
38 1 1 0 0 0 0 0.5 2 1.5 0 6
39 1 0 2 0 0.5 0 0.5 0 0 0 4
40 0 1 0 0.5 0.5 0 0.5 0 0 0 2.5
41 1 0 2 0 0.5 0.5 0 0 1.5 0 5.5
42 1 0 2 0 0.5 0.5 0.5 2 1.5 0 8
43 1 0 0 0 0 0 0.5 2 1.5 0 5
44 0 0 0 0 0 0 0.5 0 0 0 0.5
45 0 0 0 0 0.5 0 0.5 0 0 0 1
46 1 0 0 0 0.5 0 0.5 2 0 0 4
* See ref. 23 for definitions of the variables used to calculate the disease activity (DA) score. DLCO carbon monoxide diffusion in the lung; ESR
erythrocyte sedimentation rate.
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patients were classified as having lcSSc, and 24 patients
were classified as having dcSSc. The median disease
duration was 5.5 years (range 1–23 years). According to
Medsger and Steen’s criteria (24), 9 (40.9%) of 22
patients with lcSSc and 5 (20.8%) of 24 patients with
dcSSc had early disease.
All patients reported the occurrence of
Raynaud’s phenomenon after exposure to low tempera-
tures. Twenty-three patients (50%) had a modified
Rodnan skin thickness score of 14. Cutaneous ulcers
were observed in 15 (32.6%) of 46 patients. With respect
to pulmonary involvement, 11 (23.9%) of 46 patients
with SSc had pulmonary fibrosis with pulmonary hyper-
tension, and 14 (30.4%) of the 46 patients had primary
pulmonary hypertension. Evaluation of disease activity
by the European Scleroderma Study Group criteria
(22,23) indicated that 27 (58.7%) of 46 patients had
active disease (Table 1).
Quantitative studies of CECs. We identified
CECs as negative for hematopoietic marker CD45 and
positive for endothelial markers and CD34 (Figure 1).
The mean number of CECs in patients with SSc (310
cells/ml; 95% confidence interval [95% CI] 243–375) was
significantly higher than that in healthy controls (77
cells/ml; 95% CI 69–110) (P  0.001) (Table 2). When
analyzed according to disease subset, both patients with
limited SSc and patients with diffuse SSc showed signif-
icantly increased levels of CECs in comparison with
healthy controls (P  0.05 and P  0.001, respectively).
Compared with patients with limited SSc, those with
Figure 1. Flow cytometry evaluation of circulating endothelial cells (CECs) and circulating endothelial cell
progenitors (CEPs). a, Representative panel showing the analysis gate used to exclude platelets and debris (left),
and the gate used to exclude CD45-positive hematopoietic cells (right). b, Representative panel showing the
negative control, total and activated CECs, and CEPs in systemic sclerosis (SSc). ROC  receiver operating
curve; PerCP  peridin chlorophyll protein; PE  phycoerythrin; FITC  fluorescein isothiocyanate.
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diffuse SSc had a higher mean number of CECs, but the
difference did not reach statistical significance (376
cells/ml and 236 cells/ml, respectively).
CECs showed a strong correlation with disease
activity (rs 0.728, P 0.001), and the number of CECs
was significantly higher in patients with active SSc than
in patients with clinically inactive disease (P  0.001).
No correlation was found between CEC levels and
digital necrosis, skin parameters (i.e., total skin thickness
score, scleroderma), or joint and muscle involvement.
Regarding pulmonary involvement, CECs showed a
significant correlation with pulmonary pressure values in
the group of all patients with SSc (rs  0.379, P  0.05)
(data not shown) and in the subset of patients with
limited SSc (rs  0.515, P  0.05) (Figure 2A). More-
over, a significant negative correlation between CECs
and DLCO was observed only in patients with limited SSc
(rs  0.416, P  0.05) (Figure 2B), not in all patients
with SSc or in the subset with diffuse SSc. No significant
differences in CEC levels were observed between pa-
tients treated with prostanoid and untreated patients.
Activated phenotype of CECs. To assess whether
CECs are in an activated state, we analyzed them for
dual expression of P1H12 and molecules that are ex-
pressed on the endothelial surface upon activation. The
number of CECs with surface expression of E-selectin or
vascular cell adhesion molecule 1 (VCAM-1) (CD62 and
CD106, respectively) was markedly increased in patients
with SSc compared with that in healthy controls (P 
0.01 and P  0.001, respectively) (Table 2) and repre-
sented 20% of the total CECs. The number and
phenotype of activated CECs were not different be-
tween patients with diffuse SSc and those with limited
SSc. The level of CECs positive for these activation
markers was higher in patients with active disease
(namely, patients with a disease activity score of 3)
than in patients in a steady state and showed a significant
correlation with the activity score (rs  0.357, P  0.05)
(data not shown). No correlation between activated
CEC counts and digital necrosis, skin involvement, or
pulmonary parameters was found.
The mean (SD) plasma concentration of
Figure 2. Correlations of circulating endothelial cell (CEC) counts with pulmonary artery pressure values (A)
and carbon monoxide diffusion in the lung (DLCO) (B) in the subset of patients with limited cutaneous systemic
sclerosis.
Table 2. Levels of total and activated CECs and CEPs in SSc patients and healthy controls*
SSc Diffuse SSc Limited SSc Controls
Total CECs 310 (243–375) 376 (292–461) 236 (136–337) 77 (69–110)
Activated CECs
CD62 56 (38.4–73.3) 62 (37.3–86.8) 49 (24.3–81.7) 11 (0–27.9)
CD106 65 (48.3–81.5) 84 (59.4–108.3) 44 (22.6–75.6) 22 (4.2–39.8)
CEPs 122 (78–166.9) 119 (68–170) 127 (49–203.8) 28 (0–56)
* Values are the mean (95% confidence interval). For total circulating endothelial cells (CECs), P 0.001
for systemic sclerosis (SSc) and diffuse SSc versus controls, and P  0.05 for limited SSc versus controls.
For all activated CECs and circulating endothelial cell progenitors (CEPs), P  0.05 for SSc, diffuse SSc,
and limited SSc versus controls.
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E-selectin was 42.30  23.7 ng/ml in patients with SSc
and 8.8 8.7 in healthy subjects (P 0.0001). As shown
in Figure 3, the plasma E-selectin level in patients with
SSc strongly correlated with the number of total and
activated CECs (rs  0.594, P  0.01, and rs  0.371,
P  0.01, respectively). Moreover, E-selectin levels
showed a strong correlation with the disease activity
score (rs  0.604, P  0.05) (data not shown).
Quantitative studies of CEPs. According to Rafii
(17), endothelial cell progenitors were identified by
surface expression of CD34 and CD133, a novel stem
cell marker that is expressed on CEPs but not on mature
endothelial cells. As shown in Table 2, CEP concentra-
tions were significantly higher in patients with SSc than
in healthy controls (P  0.05). No significant correlation
with clinical or pathologic parameters (namely, digital
necrosis, skin and visceral involvement, and disease
activity score) was found. Notably, when patients with
SSc were stratified according to duration of disease,
those with recent-onset disease (5 years for lcSSc and
3 years for dcSSc) showed an increased number of
CEPs in comparison with patients with chronic disease
(P  0.01 and P  0.05, respectively) (data not shown).
VEGF is a major angiogenic peptide with specific
mitogenic activity on vascular endothelial cells; it is
normally secreted by cells under hypoxic conditions and
is involved in several steps of angiogenesis (27,28).
Plasma concentrations of VEGF were increased in pa-
tients with SSc compared with healthy controls (median
507 pg/ml [range 74–1,250 pg/ml] versus median 97
pg/ml [range not detectable–248 pg/ml]; P  0.001)
(data not shown), but no positive correlation was found
between circulating mature or progenitor endothelial
cells and VEGF.
DISCUSSION
The aim of our study was to investigate the
presence of CECs in patients with SSc and to evaluate
whether the number of CECs could have some relation-
ship to the different subsets and stages of the disease.
The results of the study show that 1) patients with SSc
have high levels of total and activated CECs, 2) the
presence and number of CECs are related to high levels
of disease activity and, with regard to organ involve-
ment, to the presence of pulmonary hypertension, 3) the
number of both total and activated CECs correlates with
plasma concentration of soluble E-selectin, and 4) en-
dothelial cell progenitors were also detectable in peri-
pheral blood from patients with SSc, and their number
was significantly higher in patients with early-stage dis-
ease.
To our knowledge, the finding of increased levels
of CECs in patients with SSc has not been previously
reported. However, the amount of CECs detectable in
peripheral blood has been recently proposed as a reli-
able marker of endothelial damage in different vascular
diseases, such as acute coronary syndrome (also after
coronary angioplasty), sickle cell anemia, thrombotic
thrombocytopenic purpura, rickettsial and cytomegalo-
virus infections, Behc¸et’s disease, SLE, and small-vessel
vasculitides (7–15). Thus, the detection of CECs in
patients with SSc is certainly not surprising, because
results of several histologic studies of dermal microvas-
Figure 3. Correlations of plasma levels of soluble E-selectin (sE-selectin) with concentrations of total (A) and
activated (B) circulating endothelial cells (CECs) in patients with systemic sclerosis.
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culature in this disease, which demonstrated disruption
of the normal architecture of the endothelium with loss
of intercellular junctions and progressive death of endo-
thelial cells (3–6), have suggested that endothelium may
play a key role in the pathologic process of SSc. What-
ever the underlying mechanisms of microvascular dam-
age in SSc are, it is likely that prolonged and repeated
endothelial derangement may lead to irreversible loss of
integrity, with detachment, apoptosis, and necrosis of
endothelial cells.
The number of CECs detected in patients with
SSc is not different in the subsets of patients with limited
or diffuse variants of the disorder. This is not surprising,
because for both lcSSc and dcSSc several studies have
demonstrated widespread vascular damage in lesional as
well as prelesional tissues (5,29,30). Moreover, the
amount of CECs found in SSc is comparable with that
reported in patients with different diseases characterized
by very extensive vascular injury, such as sickle cell
anemia, rickettsial and cytomegalovirus infections, and
antineutrophil cytoplasmic antibody–associated vasculit-
ides (9,11,12,15). The fact that SSc (among the vascu-
lopathies described in other connective tissue diseases)
is characterized by peculiar and particularly aggressive
endothelial damage is further confirmed by our prelim-
inary results obtained in patients with SLE. By using the
same method for detection of CECs, we observed that in
15 patients with active SLE the mean number of CECs
was higher than that in healthy subjects, but was only
moderately elevated when compared with that in pa-
tients with SSc (mean  SEM 310  32 cells/ml and
99  4.2 cells/ml, respectively; P  0.05) (Del Papa N:
unpublished observations). This finding strongly sup-
ports the conclusion that, besides the common feature of
a widespread vascular injury that is believed to be
effective in all connective tissue diseases, completely
different pathogenetic mechanisms may underlie any
single disorder.
Markers of endothelial cell activation and dam-
age, such as von Willebrand’s factor, endothelin 1,
soluble VCAM, and E-selectin, have been considered
good candidates to assess either the activity or the
severity of the disease (31). Our data, showing that the
amount of CECs closely correlated with disease activity,
strongly suggest that these cells could be an additional
marker of active disease in patients with SSc. The
clinical relevance of our results is further reinforced by
the fact that we first used a validated method for the
assessment of the disease activity (23). In contrast,
previous studies assumed that a short duration of disease
together with its rapid progression, and modification of
some acute-phase reactants or parameters (e.g., the ESR
and the CRP level) could quite well define those patients
with active disease (32–35).
The fact that the number of CECs correlated with
the disease activity scores as a whole, and not with any
single clinical feature usually thought to be indicative of
active disease, is not contradictory. The weight of any
single item included in a complex activity scale, such as
that used in the present study, can be, in fact, largely
variable, and the absolute prevalence of a single clinical
parameter, even if considered to be a strong marker of
active disease in a single patient, can be quite low in the
whole population of patients.
As far as organ involvement is concerned, we
found a close correlation between increased levels of
CECs and the presence of pulmonary hypertension in
the whole population of patients with SSc, particularly in
those with lcSSc. In the subset of patients with lcSSc, an
impairment of gas exchange was also associated with the
presence of high levels of CECs. These results may be
explained by the different mechanisms predominantly
involved in determining pulmonary hypertension in pa-
tients with lcSSc, with respect to those effective in
patients with dcSSc. Several studies have consistently
shown that damaged and dysfunctional endothelium
plays a central and critical role in the initiation and
progression of pulmonary hypertension in SSc (36,37).
The consequences of persistent endothelial dysfunction
include vasospasm, vascular remodeling, and thrombo-
sis, which are responsible for both increased pulmonary
vascular resistance and a mismatched ventilation–
perfusion ratio (38,39). These mechanisms, which can be
ascribed to a pure pulmonary endothelial disease, are
predominantly active in patients with lcSSc. Such pa-
tients have a higher risk for the development of progres-
sive pulmonary hypertension in the absence of any
interstitial fibrotic change. In contrast, in patients with
dcSSc, development of pulmonary hypertension usually
occurs late in the course of the disease and is commonly
related to pulmonary fibrosis, which has been demon-
strated often to be the final result of evolved pulmonary
alveolitis (36,37).
The finding that a relevant number of CECs have
a proadhesive phenotype is consistent with previous data
indicating that endothelial cells are present in their
activated form in the small vessels of patients with SSc.
This has been suggested by several studies that demon-
strated an up-regulation of E-selectin and intercellular
adhesion molecule (ICAM) in the skin of patients with
SSc (29,40–43), and increased plasma concentrations of
soluble forms of endothelial cell surface adhesion mol-
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ecules, including E-selectin, ICAM-1, and VCAM-1
(44,45). E-selectin is the adhesion molecule most re-
stricted to endothelial cells, and, therefore, its increased
levels in plasma and overexpression in tissues of patients
with SSc may be strictly related to endothelial activation.
In our study, this issue is confirmed by the finding that
patients with SSc also had significantly raised plasma
E-selectin concentrations, and that CEC counts strongly
correlated with plasma E-selectin levels. Based on these
observations, activated CEC counts may offer a useful
approach for the evaluation of endothelial activation in
vivo.
The detection of high numbers of CEPs in pa-
tients with SSc, particularly in those in the early stages of
disease, suggests an attempt at revascularization and
healing of ischemic tissues. It is thought that the loss of
functional and structural integrity of endothelium in SSc
might be an important stimulus for angiogenic processes
and may well explain the increase in the level of circu-
lating VEGF found in our study, as in previous studies
(46,47). These findings are consistent with recent reports
showing how the endothelial cell precursors may migrate
to the sites of active neovascularization in ischemic
tissues and may differentiate in situ into mature endo-
thelial cells (18). Further studies, however, are needed
to completely elucidate the real significance and role of
CEPs in the pathogenetic mechanisms of vascular dam-
age and repair in SSc.
In conclusion, our data provide evidence for the
presence of a relevant number of circulating mature
endothelial cells in patients with SSc, as a probable
result of shedding from affected walls of the blood
vessels. The correlation between the number of CECs
and disease activity strongly suggests that the CEC count
may be a promising marker for vascular damage and
disease progression, particularly with regard to develop-
ment of pulmonary hypertension in patients with the
limited cutaneous variant of SSc. Furthermore, the
possibility of identifying patients with active vascular
damage could be useful both for selecting patients
suitable for a more aggressive therapeutic approach and
for monitoring the efficacy of such a therapeutic inter-
vention. This study may provide a basis on which to test
these hypotheses in larger, longitudinal studies.
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